Created in 2010 (France), TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly own 306 sister brands and 4959 competing brands. The TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly brand is owned by Ipsen, a company listed in Paris. The International Securities Identification Number (ISIN) of Ipsen is FR0010259150. TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly belongs to the Drug Manufacturers business sector.

TULIPIA Trial Using BIM23A760 dose Levels In Patients In Acromegaly is a brand of Ipsen (IPN) Other brands

Buy Ipsen share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Other brands
Ipsen